ArticleBioactive materials2026
Spatiotemporal reprogramming of cardiac lipid metabolism by platelet-engineered RNA therapy epigenetically modulate heart repair and regeneration.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial anchoring of lipid metabolism shapes immune fate in the tumor microenvironment.Lipids in health and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease remains a leading global cause of morbidity and mortality, driven by the irreversible loss of cardiomyocytes (CMs) and their limited regenerative capacity. Suppression of fatty acid oxidation (FAO) has shown potential to restore CMs proliferation, but global inhibition of mitochondrial FAO usually results in lipid accumulation and metabolic stress. Targeting fatty acid uptake via CD36, a key transmembrane transporter, offers a more selective strategy to constrain FAO while minimizing lipotoxicity. Here, we report a bioresponsive siRNA delivery system composed of platelet-encapsulated mesoporous silica nanoparticles (Plt-MSNs) loaded with CD36-targeting siRNA. Exploiting the open canalicular system (OCS), platelets internalize siRNA cargo and enable specific delivery via their innate homing ability to sites of myocardial injury. In a murine ischemia-reperfusion model, Plt-MSNs achieved targeted delivery and stimulus-responsive release of siCD36, effectively reprogrammed CMs lipid metabolism, remodeled the epigenetic landscape, that eventually promoted proliferation without lipid toxicity. This approach offers a platform for regenerative gene therapy through metabolic-epigenetic reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.